# Application of Molecularly Imprinted Polymers in the Analysis of Waters and Wastewaters
## 6 Conclusions
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline \multicolumn{2}{c}{**Kind of Pharmaceutical**} & \multirow{2}{*}{**Analyte**} & \multirow{2}{*}{**Monomer**} & \multirow{2}{*}{**Modifiers**} & \multirow{2}{*}{**Analytical Technique**} & \multirow{2}{*}{**Sample**} & \multirow{2}{*}{**Linear Range**} & \multirow{2}{*}{**LOD**} & \multirow{2}{*}{**Ref.**} \\ \hline \multirow{4}{*}{Antibiotics} & Ciprofloxacin & MAA & Ch-AuMIP & CV and DPV & Mineral and tap water & \(\mu\)mol L\({}^{-1}\) & 210 nmol L\({}^{-1}\) & [187] \\  & Nalidixic acid & MAA & NA-MIP & spectrophonometry & Pills and seawater & 1–150 \(\mu\)g L\({}^{-1}\) & 0.2 \(\mu\)g L\({}^{-1}\) & [188] \\  & Erythromycin & mPD & Ery-MIP & DPV & Tap water & 2–16 nM & 0.1 nM & [184] \\  & Norfloxacin & MAA & MIP-CP & spectrophonometry & Aqueous & 10–100 & 2.59 ng mL\({}^{-1}\) & [189] \\  & Chloramphenicol & MAA & MIP-S-BiOBr-ITO & EIS & Water sample & \(10^{-2}\)–\(10^{-3}\) & 3.02 pg mL\({}^{-1}\) & [190] \\ \hline \multirow{4}{*}{Antidepressant} & Venlafaxine & p-vinyl & p-sirpoxide acid & MASE-MIP & HPLC & Water samples & 5–100 & 0.13 ng mL\({}^{-1}\) & [183] \\  & Sertraline & MAA & SER-MIPs & HPLC-DAD & Wastewater & 2.79–120.7 & 0.41 \(\mu\)g L\({}^{-1}\) & [185] \\ \hline Antiretroviral & Efaviernz & 2-VP & MIPs & HPLC-DAD & Wastewater & - & - & [191] \\ \hline \multirow{4}{*}{Analgesics} & ketoprofen & 2-VP & MIPS & HPLC & Wastewater & 1–1000 & 0.3 \(\mu\)g L\({}^{-1}\) & [192] \\  & Naproven & MAA & MWCNTs- & EME & HPLC-UV & Wastewater & 1–100 \(\mu\)g L\({}^{-1}\) & 0.3 \(\mu\)g L\({}^{-1}\) & [193] \\  & Acetaminophen & MAA & Ace-MIPs & spectrophonometry & Pills and seawater & 1–300 & 0.34 nmol L\({}^{-1}\) & [188] \\  & Acetaminophen & APTES & MIP-Capped L-C5y-2/m5 & Fluorescence & & & & \\  & Acetaminophen & APTES & LC-C5y-2/m5 & emission & Water sample & - & - & [194] \\  & & QD &ometry & & & & & \\ \hline \multirow{4}{*}{Anticonvulsant} & Carbamazepine & MAA & PMIP-CBZ & HPLC & Various water & 0.2–250 & 0.082 & \\  & Phenylton & AAm & MISPE & HPLC & samples & ng mL\({}^{-1}\) & ng mL\({}^{-1}\) & [186] \\  & & & MSPE & HPLC & Wastewater & 2–30 \(\mu\)g mL\({}^{-1}\) & 0.7 \(\mu\)g mL\({}^{-1}\) & [195] \\ \hline \multirow{4}{*}{Antisepatic} & Tricosan & AAm & Au-SPE-MIP & DPV and EIS & Wastewater & 0.1–1000 & 0.23 pg mL\({}^{-1}\) & [196] \\  & Fenoprofen & 2-VP & MIPs & HPLC & Wastewater & 24–58 & 0.64 ng mL\({}^{-1}\) & [197] \\  & Diclofenac & AT & MIP-DCF & spectrophotometry & Water sample & 1–25 mg L\({}^{-1}\) & - & [198] \\  & drug & & ZnO- & UV-Vis & & & & \\  & & & NP8@MLEL- & spectrophonometry & Water media & 0.1–10 mg L\({}^{-1}\) & 0.008 mg L\({}^{-1}\) & [199] \\  & & & The & & & & & \\ \hline \multirow{4}{*}{Hormones} & Progesterone & PY & MIPs & GC-FID & Hospital wastewater & 1.25–5000 & 0.625 & \\  & Estrid & MAA & MMIP & HPLC & water sample & - & - & [200] \\ \cline{1-1}  & Estro & MAA & MMIP & HPLC & Water sample & - & - & [201] \\ \hline \multicolumn{2}{c}{**(AT)** allythiourea, **(EIS)** electrochemical impedance spectroscopy, **(FTIR)** Fourier transmission infrared spectra, **(GCE)** glassy carbon electrode, **(GC-FID)** Gas chromatography coupled with Flame Ionization Detector, **(\({}^{\textbf{t}}\)H NMR)** Nuclear Magnetic Resonance, **(HPLC-DAD)** high performance liquid chromatograph coupled with a diode array detector, **(MAA)** Methacrylic acid, **(mPD)** m-phenylenediamine, **(PY)** pyrrole, **(UV)** ultraviolet, **(Z-VP)** 2-vinylpyridine. & & & & \\ \hline \end{tabular}
\end{table} 
Table 5: Application of MIPs in the determination of pharmaceutical residues in waters and wastewaters. M.G.M. ; R.M.E.N. and M.T. ; supervision, R.M.E.N. All authors have read and agreed to the published version of the manuscript. This research received no external funding. **Institutional Review Board Statement**: Not Applicable. **Informed Consent Statement**: Not Applicable. **Data Availability Statement**: Not Applicable. **Conflicts of Interest**: The authors declare no conflict of interest.